We also detail the role of the CYP4A11 and CYP2E1 arachidonic metabolites and their possible functional role in portal hypertension in hepatic cirrhosis and suggest alteration in these pathways may be therapeutic targets in the treatment of chronic liver disease. The gene discussed is CYP2E1; the disease is liver disorder.